Tadocizumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Integrin αIIbβ3 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C2107H3252N562O673S12 |
| Molar mass | 47.6 kg/mol |
  (what is this?) (verify) |
|
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]
The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
References[edit]
- ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
